Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Enanta Pharmaceuticals reports strong Q1 earnings and advances antiviral programs

Enanta Pharmaceuticals delivered solid financial performance in Q1 2023, backed by revenue from AbbVie's MAVYRET sales and a strong cash position for future operations.
The company's focus on advancing their COVID-19 program, RSV therapeutics, and antiviral research programs demonstrates a commitment to addressing critical medical challenges.
While Enanta faces challenges in clinical development and market competition, opportunities in expanding their antiviral portfolio and presenting upcoming data offer avenues for growth.

Enanta Pharmaceuticals excels in COVID-19 treatment pipeline expansion

Enanta Pharmaceuticals showcased positive outcomes from the Phase 2 study of EDP-235 for COVID-19, emphasizing safety and symptom improvement.
The company's diversified pipeline, financial flexibility enhancement, and proactive strategic planning reflect a robust operational framework.
Challenges include demonstrating direct antiviral effects of EDP-235 and addressing regulatory and safety considerations in patient populations.
Opportunities lie in expanding therapeutic reach, capitalizing on market prospects, and addressing evolving healthcare needs in COVID-19 treatment.
Analyst interest in EDP-235's benefits, market opportunities, and patient population considerations underscores investor confidence and strategic relevance.

Enanta Pharmaceuticals reports positive Q3 results and growth opportunities

Enanta Pharmaceuticals showcased progress in RSV and COVID-19 programs with positive Phase I data.
Financially, the company reported revenue of $18.9 million and expects cash reserves to support operations into 2027.
Focus on high-risk patient populations and exploration of partnerships present growth opportunities.

Enanta Pharmaceuticals reports strong Q4 earnings, advances RSV program

Enanta Pharmaceuticals reported solid financial performance in Q4 2023, with a focus on cost reduction and strategic allocation of resources.
The company's RSV program progress and adjustments to prioritize key studies demonstrate a commitment to advancing its pipeline and making informed decisions.
While facing challenges in clinical trial recruitment and navigating the impact of COVID, Enanta remains focused on exploring new therapeutic avenues and leveraging opportunities for growth.
Ongoing discussions with the FDA, progress in key studies, and strategic decision-making underscore Enanta's efforts to drive innovation and address medical needs.

Enanta Pharmaceuticals reports Q1 revenue, progresses in RSV and immunology

Enanta Pharmaceuticals is progressing well in RSV and immunology programs, with a focus on oral treatments for respiratory syncytial virus and chronic spontaneous urticaria.
Financially, the company reported total revenue of $18 million, decreased R&D expenses, and ended the quarter with $337 million in cash and marketable securities.
Challenges include ongoing financial losses, the need for successful Phase 2 studies, and developing a best-in-disease oral KIT inhibitor.
Opportunities lie in market demand for oral treatments, entering markets with high unmet medical needs, and developing compounds with selectivity against KIT kinase.

Enanta Pharmaceuticals reports solid Q2 earnings amidst pipeline advancements

Enanta Pharmaceuticals is strategically positioned with a focus on virology and immunology, strong financial stability, and promising pipeline candidates like zelicapavir and EDP-323.
While facing challenges such as patent litigation, the company's emphasis on innovation and potential expansion into new indications presents exciting growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938

Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q1 2022 Results - Earnings Call Transcript

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Enanta Pharmaceuticals (ENTA) Might Surprise This Earnings Season

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2021

Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2021

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Provide Updates on its R&D Programs and Outlook for 2022 at the 40th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2022 at the 40th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

Bicycle Therapeutics Plc - ADR

BioNTech SE

Avid Bioservices

IVERIC bio Inc

Moderna

Prothena

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

7 A-Rated Biotechs to Buy for the Long Run

The stock price of Enanta Pharmaceuticals Inc (NASDAQ: ENTA) increased by over 10% during intraday trading today. This is why it happened.

Enanta Pharmaceuticals (ENTA) Stock: Why The Price Surged Today

Enanta Pharmaceuticals, Inc. (ENTA) CEO Dr. Jay Luly on Q4 Fiscal 2021 Result - Earnings Call Transcript

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET

Is a Surprise Coming for Enanta Pharmaceuticals (ENTA) This Earnings Season?

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Participate in December Investor Conferences

Enanta Pharmaceuticals to Participate in December Investor Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus Program

Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta to Host Conference Call on November 22 to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021

Enanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core Inhibitor.

Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core Inhibitor

Cara Therapeutics

Ocugen, Inc.

These biotech stocks have recently been responsible for a slew of rocketship emojis.

3 Explosive Biotech Stocks -- Could They Shoot Even Higher?

Catalyst Pharmaceuticals

Molecular Templates

Xencor

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.

4 Small Drug Stocks That Hold Promise Despite Industry Challenges

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has reported new preclinical data for EDP-235, its recently announced lead oral protease inhibitor for COVID-19.  The data were presented at the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV)–World Health Organization (WHO) Virtual Conference 2021.

Enanta Plans To Start Human Trials For Its COVID-19 Candidate In 2022

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference

Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference 2021

Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Enanta Pharmaceuticals (ENTA) Moves 10.6% Higher: Will This Strength Last?

WATERTOWN, Mass.--(BUSINESS WIRE)--New Preclinical Data for EDP-235, Enanta's Oral Protease Inhibitor for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference

New Preclinical Data for EDP-235, Enanta's Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

News for Enanta Pharmaceuticals Stock (ENTA)